Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs QUALCOMM, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while QUALCOMM, Inc. trades at $184.76 (market cap $199.37B). The key difference: QUALCOMM, Inc. is far larger — about 5× Alnylam Pharmaceuticals, Inc.'s market cap, and QUALCOMM, Inc. pays a 1.95% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | QCOM | |
|---|---|---|
Market Cap | $39.89B | $199.37B |
Sector | Health | Technology |
52-Week High | $491.22 | $251.10 |
52-Week Low | $278.09 | $124.07 |
Enterprise Value | $38.15B | $204.85B |
Dividend Yield | — | 1.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Qualcomm (QCOM) trades at $189.16, down 1.01% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported revenue of $44.28 billion in 2025, with a net income margin of 22.31% and robust cash flow from operations of $14.01 billion. Recent news highlights its push into AI and data centers, though competition from Nvidia in the PC chip market poses challenges.
The outlook for QCOM is positive, driven by diversification into automotive and AI, with a consensus price target of $221.21 implying 17% upside. Risks include smartphone market softness and margin pressures, but strong analyst buy ratings (42.65%) and institutional support suggest confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
